Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.58 |
| ▸ | JAK2 | O60674 | 2/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 2/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.41 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | FER | P16591 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29497531 | 1.00 | PDPK1 (0.58) | PDPK1JAK2DYRK1ACYP2A6GSK3B | |
| SCHEMBL660142 | 0.86 | PDPK1 (0.58) | PDPK1JAK2DYRK1ACYP2A6GSK3B | |
| SCHEMBL3538242 | 0.80 | TTK (0.54) | CYP2A6CHEK1KDRCDK2 | |
| SCHEMBL23087789 | 0.79 | PRMT5 (0.44) | PDPK1JAK2DYRK1ACYP2A6GSK3B | |
| SCHEMBL29915098 | 0.79 | PRMT5 (0.44) | PDPK1JAK2DYRK1ACYP2A6GSK3B | |
| SCHEMBL15304355 | 0.79 | ITK (0.46) | CHEK1KDRPIM3CDK2PIM1 | |
| SCHEMBL3537177 | 0.79 | MAP2K4 (0.51) | CHEK1CDK2 | |
| SCHEMBL5211222 | 0.79 | MAP2K4 (0.48) | DYRK1AGSK3BCHEK1KDRCDK2 | |
| SCHEMBL29955085 | 0.79 | ITK (0.46) | CHEK1KDRPIM3CDK2PIM1 | |
| SCHEMBL29955404 | 0.79 | PDPK1 (0.54) | PDPK1JAK2GSK3BCHEK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4003977-B1 | PYRIDINE DERIVATIVES AS CALCIUM-ACTIVATED CHLORIDE CHANNEL MODULATORS | TMEM16A LTD (GB) | 2026-04-15 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12545658-B2 | Pyridine derivatives as calcium-activated chloride channel modulators | TMEM16A LIMITED (GB) | 2026-02-10 | — | — | US | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3728199-B1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2025-05-14 | — | — | EP | disclosed |
| EP-4186908-B1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2025-05-07 | — | — | EP | disclosed |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130029968-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014567-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012123522-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20110245179-A1 | Composition for Prevention or Treatment of Heart Failure | PARK WOO JIN | 2011-10-06 | — | — | US | disclosed |
| US-20110245179-A1 | Composition for Prevention or Treatment of Heart Failure | PARK WOO JIN | 2011-10-06 | — | — | US | disclosed |
| US-20110245179-A1 | Composition for Prevention or Treatment of Heart Failure | PARK WOO JIN | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029968-A1 | INDAZOLES | CYP11B2, CYP11B1, IL33 | PDPK1 1902/4885JAK2 1289/4885DYRK1A 3287/4885 |
| US-20110245179-A1 | Composition for Prevention or Treatment of Heart Failure | ATP2A3, ATP2A1, MYLK2 | PDPK1 193/4885JAK2 3858/4885DYRK1A 3065/4885 |
| US-12545658-B2 | Pyridine derivatives as calcium-activated chloride channel modulators | CACNA1E, CACNA1D, CACNA1B | PDPK1 1429/4885JAK2 3045/4885DYRK1A 4217/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | PDPK1 2923/4885JAK2 4120/4885DYRK1A 4137/4885 |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | PDPK1 3178/4885JAK2 1051/4885DYRK1A 1618/4885 |
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | PDPK1 783/4885JAK2 2/4885DYRK1A 752/4885 |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | PDPK1 1254/4885JAK2 1197/4885DYRK1A 2084/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | PDPK1 3178/4885JAK2 1051/4885DYRK1A 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.